Immunome reports a Form 144 filing for shares covering the period ending June 30, according to Investing.com. Form 144 is a notice used in the U.S. to disclose plans for the resale of restricted or control shares under SEC rules. While the filing is presented as covering “30 June,” the available source material does not include additional details such as the number of shares, the relationship of the seller(s) to the company, the intended sale timing, or whether sales occur immediately after the notice. The disclosure is typically informational, indicating that certain shareholders may be preparing to sell eligible shares subject to applicable legal and trading requirements. The snippet provided does not mention any other related corporate actions, financial results, or commentary from management. Based on the source, the key development is the company’s submission of the Form 144 notice referencing June 30, with further specifics remaining unspecified in the provided text.